NEW
YORK, May 22, 2025 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Cerevel
Therapeutics Holdings, Inc. (NYSE: ABBV).
Shareholders who purchased shares of ABBV during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=149526&from=4
CLASS PERIOD: This lawsuit is on behalf of all persons or
entities that: (a) sold or otherwise disposed of the
publicly-traded common stock of Cerevel during the period from
October 11, 2023 through August 1, 2024, inclusive. (b) held shares of
Cerevel as of the January 8, 2024
record date and were entitled to vote on the merger of Cerevel and
AbbVie Inc. (c) sold shares of Cerevel stock contemporaneously with
Bain Capital's purchase of shares on or about October 16, 2023.
ALLEGATIONS: According to the complaint, Cerevel's
October 16, 2023 secondary stock
offering (the "October Offering" or "Offering") documents and other
public statements omitted material facts regarding AbbVie's
interest in acquiring Cerevel at a price well in excess of the
$22.81 per share Offering price,
artificially deflating Cerevel's stock price until the merger was
announced. Moreover, Cerevel's controlling shareholder, Bain
Capital Investors, LLC ("Bain"), acquired Cerevel shares from the
October Offering at an artificially depressed price while
allegedly in possession of material nonpublic
information regarding AbbVie's interest. On December 6, 2023, Cerevel publicly announced that
AbbVie agreed to acquire Cerevel for $45 per share. The merger allowed Bain to receive
a windfall of more than $120 million
on the shares it acquired at the artificially depressed Offering
price. In addition, Cerevel's January 18,
2024 Proxy statement misled investors regarding the true
nature and timing of AbbVie's interest in Cerevel.
DEADLINE: June 3, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=149526&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of ABBV during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is June 3, 2025. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cerevel-therapeutics-holdings-inc-sued-for-securities-law-violations---contact-the-gross-law-firm-before-june-3-2025-to-discuss-your-rights--abbv-302462518.html
SOURCE The Gross Law Firm
